stockrowPraxis Precision Medicines, Inc.
PRAX Healthcare Biotechnology
Praxis Precision Medicines, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $8.6 million, up 249.5% from fiscal 2023.
- Revenue
- +1,349.1%
- EPS
- +13.3%
- Free cash flow
- −43.5%
Quarter to June 2026, against a year earlier
Follow PRAX
Alert me
Praxis Precision Medicines, Inc. (PRAX) Return on assets
Praxis Precision Medicines, Inc.'s return on assets over the twelve months to 30 June 2026 was −36.8%, up 5.9 percentage points from fiscal 2025 (−42.7%). Over the past ten years it has ranged from −294.8% (fiscal 2018) to −40.1% (fiscal 2020); the current reading is higher than 88% of that period. That is above the Biotechnology industry median of −45.6% and below the Healthcare sector median of −29.3%.
Return on assets, annual
Embed this chart
Annual newest first
| Period | Return on assets | Change (points) |
|---|---|---|
| FY2025 | −42.7% | 21.35 |
| FY2024 | −64.0% | 57.38 |
| FY2023 | −121.4% | (16.46) |
| FY2022 | −105.0% | (48.88) |
| FY2021 | −56.1% | (15.99) |
| FY2020 | −40.1% | 80.42 |
| FY2019 | −120.5% | 174.25 |
| FY2018 | −294.8% | — |
Against its own ten years
Return on assets against peers
| Company | Return on assets |
|---|---|
| CORT Corcept Therapeutics Incorporated compare | 17.2% |
| KRYS Krystal Biotech, Inc. compare | 15.9% |
| ARWR Arrowhead Pharmaceuticals, Inc. compare | −18.3% |
| AXSM Axsome Therapeutics, Inc. compare | −21.0% |
| SYRE Spyre Therapeutics, Inc. compare | −30.9% |
| PRAX Praxis Precision Medicines, Inc. | −36.8% |
| RYTM Rhythm Pharmaceuticals, Inc. compare | −41.8% |
| CYTK Cytokinetics, Incorporated compare | −47.7% |
| ABVX Abivax SA Sponsored ADR compare | −137.7% |
| Biotechnology industry median | −45.6% |
| Healthcare sector median | −29.3% |
| Market median | 0.00% |
What Return on assets is
ROA tells an investor how much profit a company earns for shareholders from the assets it uses to run its business.
Annual: Net Income Allotted to Shareholders ÷ Average Assets; TTM: Net Income Allotted to Shareholders ÷ Average Assets (latest quarter)